$8.44
1.17% day before yesterday
Nasdaq, Dec 27, 10:00 pm CET
ISIN
US67576A1007
Symbol
OCUL
Sector
Industry

Ocular Therapeutix Inc Stock price

$8.44
-1.62 16.10% 1M
+1.68 24.85% 6M
+3.98 89.24% YTD
+3.94 87.56% 1Y
+1.57 22.85% 3Y
+4.25 101.43% 5Y
-14.76 63.62% 10Y
Nasdaq, Closing price Fri, Dec 27 2024
-0.10 1.17%
ISIN
US67576A1007
Symbol
OCUL
Sector
Industry

Key metrics

Market capitalization $1.33b
Enterprise Value $974.81m
P/E (TTM) P/E ratio negative
EV/FCF (TTM) EV/FCF negative
EV/Sales (TTM) EV/Sales 15.87
P/S ratio (TTM) P/S ratio 21.60
P/B ratio (TTM) P/B ratio 3.76
Revenue growth (TTM) Revenue growth 6.45%
Revenue (TTM) Revenue $61.44m
EBIT (operating result TTM) EBIT $-141.25m
Free Cash Flow (TTM) Free Cash Flow $-114.06m
Cash position $427.22m
EPS (TTM) EPS $-1.32
P/E forward negative
P/S forward 20.82
EV/Sales forward 15.29
Short interest 8.16%
Show more

Is Ocular Therapeutix Inc a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 6,886 stocks worldwide.

Ocular Therapeutix Inc Stock Analysis

Unlock Scores for Free

Analyst Opinions

10 Analysts have issued a Ocular Therapeutix Inc forecast:

10x Buy
100%

Analyst Opinions

10 Analysts have issued a Ocular Therapeutix Inc forecast:

Buy
100%

Financial data from Ocular Therapeutix Inc

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Sep '24
+/-
%
61 61
6% 6%
100%
- Direct Costs 5.78 5.78
18% 18%
9%
56 56
5% 5%
91%
- Selling and Administrative Expenses 90 90
23% 23%
147%
- Research and Development Expense 103 103
76% 76%
167%
-137 -137
74% 74%
-224%
- Depreciation and Amortization 3.79 3.79
50% 50%
6%
EBIT (Operating Income) EBIT -141 -141
73% 73%
-230%
Net Profit -174 -174
160% 160%
-284%

In millions USD.

Don't miss a Thing! We will send you all news about Ocular Therapeutix Inc directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Ocular Therapeutix Inc Stock News

Neutral
GlobeNewsWire
16 days ago
BEDFORD, Mass., Dec. 13, 2024 (GLOBE NEWSWIRE) -- Ocular Therapeutix, Inc. (NASDAQ:OCUL, “Ocular”), a biopharmaceutical company committed to improving vision in the real world through the development and commercialization of innovative therapies for retinal diseases and other eye conditions, today announced that it has agreed to grant inducement awards to one newly hired employee. The awards we...
Neutral
GlobeNewsWire
19 days ago
BEDFORD, Mass., Dec. 10, 2024 (GLOBE NEWSWIRE) -- Ocular Therapeutix, Inc. (NASDAQ: OCUL, “Ocular”, the “Company”), a biopharmaceutical company committed to improving vision in the real world through the development and commercialization of innovative therapies for retinal diseases and other eye conditions, today announced that the Company will present at the 43rd Annual J.P. Morgan Healthcare ...
Neutral
GlobeNewsWire
27 days ago
SOL-1 is the first registrational trial for AXPAXLI™ in wet AMD Topline clinical data from SOL-1 expected in Q4 2025 Active clinical trial sites enrolling patients directly into second registrational trial, SOL-R, while additional sites continue to be activated BEDFORD, Mass., Dec. 02, 2024 (GLOBE NEWSWIRE) -- Ocular Therapeutix, Inc. (NASDAQ: OCUL, “Ocular”, the “Company”), a biopharmaceutical...
More Ocular Therapeutix Inc News

Company Profile

Ocular Therapeutix, Inc. is a biopharmaceutical company, which engages in the development and commercialization of therapies for diseases and conditions of the eye. Its product pipeline includes Dextenza, OTX-TP, and OTX-TIC. The company was founded by Amarpreet S. Sawhney and Farhad Khosravi on September 12, 2006 and is headquartered in Bedford, MA.

Head office United States
CEO Pravin Dugel
Employees 267
Founded 2006
Website www.ocutx.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today